Dr Matthew Franklin
BA, MSc, PhD
Population Health, School of Medicine and Population Health
Senior Research Fellow
+44 114 222 4226
Full contact details
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
91̽»¨
S1 4DA
- Profile
-
I completed my BA in Economics and MSc in Economics and Health Economics at the University of 91̽»¨ in 2007 and 2008, respectively. I then moved to the University of Nottingham in 2008, working as a Health Economist Research Associate, as well as starting my PhD in Health Economics in 2010. I completed and passed my Viva for my PhD thesis, titled "The role of utility, health, and capabilities in economic evaluation: a case study in frail older people", as of December 2014.
My research has broadly focussed on estimating the comparative cost-effectiveness of different health and social care interventions using economic evaluation methods both within-study and for modelling-based analyses. I am particularly interested in the conduct of economic evaluations that use real-world data to support trials and observational studies. I have a keen interest in the philosophies of data science tasks, such as working out what we want to estimate, why, and to inform whom, and then working through if this is a description, prediction, or causal inference task. By understanding these philosophies, we can better work through the appropriate methods for the task at hand. I am particularly interested in tasks when causal inference is of interest, which is often the key interest in economic evaluation.
- Research interests
-
I have a keen interest in the components of economic evaluation related to outcomes (particularly preference-based outcomes), resource use and costs. I have explored both the conceptual underpinning of relevant outcomes for economic evaluation (such as the focus on health and utilities, alongside other perspectives such as the capability approach), the estimation of these outcomes (such as appropriately estimating health utility, health state utilities, and quality-adjusted life years [QALYs]), and the psychometric properties of patient-reported outcomes with a focus on construct validity and responsiveness.
I have explored the use of both self-reported and electronic methods for capturing resource use, with a keen interest in the use of real-world data such as from administrative databases and electronic health records. I am also interested in how such real-world data can be used for costing studies, such as understanding the economic burden of health conditions and the affordability of current health and social care systems. I have used such considerations to explore what is a relevant and appropriate economic evidence-based to inform local compared to national decision-makers, for medical compared to public health considerations, in the context of service evaluations compared to research studies, and when considering average effects compared to the potential inequalities and inequities of such effects.
Economic evaluation and causal inference have a broad range of philosophies, methods, and uses, and I’m generally interested in exploring the nuances and complexities of each of these aspects. I have worked across a range of conditions and population groups, but I have a keen interest in mental health across the lifespan.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . Advances in Therapy.
- . PharmacoEconomics - Open.
- . Applied Health Economics and Health Policy.
- . Quality of Life Research, 32(10), 2763-2778.
- . Applied Health Economics and Health Policy, 21, 547-558.
- . Value in Health, 25(6), 1018-1029.
- . Quality of Life Research, 30(9), 2633-2647.
- . PharmacoEconomics, 38(7), 665-681.
- . Age and Ageing.
- . The Patient - Patient-Centered Outcomes Research, 12(4), 405-417.
- . PharmacoEconomics, 37(5), 631-643.
- . BMC Medical Research Methodology, 19.
- . Medical Decision Making, 38(1), 79-94.
- . PharmacoEconomics, 35(5), 561-573.
- . Circulation, 134(20), 1568-1578.
- . Age and Ageing, 43(5), 703-707.
- . Oncology and Therapy.
Chapters
- , Mental Health Economics (pp. 89-119). Springer International Publishing
- , Mental Health Economics (pp. 121-153). Springer International Publishing
Reports
All publications
Journal articles
- . Advances in Therapy.
- . PharmacoEconomics - Open.
- . Applied Health Economics and Health Policy.
- . BMJ Open, 14(1), e077220-e077220.
- . NIHR Open Research, 3(28).
- . BMJ Open, 13(10).
- . eClinicalMedicine, 64, 102192-102192.
- . Quality of Life Research, 32(10), 2763-2778.
- . BMC Health Services Research, 23(1).
- . Applied Health Economics and Health Policy, 21, 547-558.
- . Value in Health.
- . BMC Public Health, 23(1).
- . Value in Health.
- . Applied Health Economics and Health Policy, 20(6), 783-792.
- . Cost Effectiveness and Resource Allocation, 20(1).
- . Applied Health Economics and Health Policy, 20(6), 793-802.
- . Medical Decision Making, 42(8), 999-1009.
- . BMC Health Services Research, 22(1).
- . BMC Health Services Research, 22(1).
- . Value in Health, 25(6), 1018-1029.
- . Evidence Based Mental Health, 24(4).
- . Quality of Life Research, 30(9), 2633-2647.
- . Journal of Affective Disorders, 276, 848-849.
- . PharmacoEconomics, 38(7), 665-681.
- . npj Digital Medicine, 3(1).
- . Age and Ageing.
- . Quality of Life Research, 28(8), 2041-2056.
- . The Patient - Patient-Centered Outcomes Research, 12(4), 405-417.
- . PharmacoEconomics, 37(5), 631-643.
- . BMC Medical Research Methodology, 19.
- . BMJ Open, 8(4).
- . BMC Psychiatry, 18.
- . Health Technology Assessment, 22(11), 1-204.
- . Medical Decision Making, 38(1), 79-94.
- . PharmacoEconomics, 35(5), 561-573.
- . Health Technology Assessment, 20(93), 1-154.
- . Circulation, 134(20), 1568-1578.
- . PLOS ONE, 10(12), e0140662-e0140662.
- . PloS one, 10(5), e0121340.
- . Programme Grants for Applied Research, 3(4), 1-410.
- . Age and Ageing, 43(5), 703-707.
- . PharmacoEconomics, 32(6), 573-590.
- . Age and Ageing, 43(1), 97-103.
- . BMJ, 347(oct08 2), f5874-f5874.
- . Age and Ageing, 42(6), 747-753.
- . Age and Ageing, 42(6), 776-781.
- . BMC Family Practice, 13(1).
- . The Lancet, 379(9823), 1310-1319.
- . Trials, 12(1).
- . Oncology and Therapy.
- . The European Journal of Health Economics.
Chapters
- , Mental Health Economics (pp. 89-119). Springer International Publishing
- , Mental Health Economics (pp. 121-153). Springer International Publishing
Conference proceedings papers
- COMBINING CAUSAL INFERENCE AND WITHIN-TRIAL ECONOMIC EVALUATION METHODS TO ASSESS THE COST-EFFECTIVENESS OF A MENTAL HEALTH SERVICE USING REAL-WORLD DATA: THE QUASI-EXPERIMENTAL ADAPT STUDY. VALUE IN HEALTH, Vol. 26(12) (pp S87-S87)
- . Blood, Vol. 140(Supplement 1) (pp 10885-10886)
- SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIVING WITH IDIOPATHIC MULTICENTRIC CASTLEMANS DISEASE: DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF A BESPOKE INTERNATIONAL PATIENT AND CAREGIVER SURVEY. VALUE IN HEALTH, Vol. 25(12) (pp S416-S417)
- Self-reported and electronic resource use for trial-based economic evaluations: the current state of play in England and considerations for the future. TRIALS, Vol. 18
- . 1.6 General Practice and Primary Care
- . Value in Health, Vol. 19(7) (pp A608-A608)
- . Value in Health, Vol. 16(7) (pp A335-A335)
- . Value in Health, Vol. 16(7) (pp A578-A578)
- . Value in Health, Vol. 16(3) (pp A206-A206)
- . Value in Health, Vol. 16(3) (pp A20-A20)
- . Value in Health, Vol. 16(3) (pp A196-A196)
Reports
- 91̽»¨ City Region Test Bed, ‘Perfect Patient Pathway’ final evaluation report
- Supporting the routine collection of patient reported outcome measures in the National Clinical Audit Work Package 2. How should PROMS data be collected?
Datasets
Presentations
- .
- PB2708: SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE IN PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN’S DISEASE (IMCD): AN EXPLORATORY ANALYSIS OF THE SURVEY’S INTERNAL CONSTRUCT VALIDITY.
Other
Preprints
- Teaching activities
-
Course Deputy Director for MSc Health Economics and Decision Modelling (HEDM)
- Professional activities and memberships
-
Health Economics and Decision Science (HEDS) section lead for Knowledge Exchange (KE)
Member of the
co-lead for Real-World Evidence for Health Technology Assessment